Abstract
Toxic shock syndrome is an acute, multi-systemic, toxin-mediated illness caused by toxin-producing strains of Staphylococcus aureus and Streptococcus species. Streptococcal toxic shock syndrome is usually caused by Streptococcus pyogenes but Group G streptococcal toxic shock syndrome is rare. Herein, we report a case of group G streptococcal toxic shock syndrome that was successfully treated with toxin reducing antibiotics and intravenous immunoglobulin therapies.
References
3. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 1987. 317:146–149.
4. Bisno AL, Stevens DL. Mandell GL, Bennett JE, Dolin R, editors. Streptococcus pyogenes. Priniciples and practice of Infectious diseases. 2005. 6th ed. Philadelphia: Elsevier Inc.;2373.
5. Wagner JG, Schlievert PM, Assimacopoulos AP, Stoehr JA, Carson PJ, Komadina K. Acute group G streptococcal myositis associated with streptococcal toxic shock syndrome: case report and review. Clin Infect Dis. 1996. 23:1159–1161.
6. Kugi M, Tojo H, Haraga I, Takata T, Handa K, Tanaka K. Toxic shock-like syndrome caused by group G Streptococcus. J Infect. 1998. 37:308–309.
7. Horii T, Izumida S, Takeuchi K, Tada T, Ishikawa J, Tsuboi K. Acute peritonitis and salpingitis associated with streptococcal toxic shock syndrome caused by Lancefield group G alpha-haemolytic Streptococcus dysgalactiae subsp. equisimilis. J Med Microbiol. 2006. 55:953–956.
8. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA. 1993. 269:390–391.
9. Sendi P, Johansson L, Norrby-Teglund A. Invasive group B Streptococcal disease in non-pregnant adults: a review with emphasis on skin and soft-tissue infections. Infection. 2008. 36:100–111.
10. Hashikawa S, Iinuma Y, Furushita M, Ohkura T, Nada T, Torii K, Hasegawa T, Ohta M. Characterization of group C and G streptococcal strains that cause streptococcal toxic shock syndrome. J Clin Microbiol. 2004. 42:186–192.
11. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000. 13:470–511.
12. Tan JS, File TM. Yu VL, Weber R, Raoult D, editors. Streptococcus species. Antimicrobial therapy and vaccines. 2002. 2nd ed. New York: Apple tree productions, LLC;736.
13. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J. 1999. 18:1096–1100.
14. Mascini EM, Jansze M, Schouls LM, Verhoef J, Van Dijk H. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents. 2001. 18:395–398.
15. Norrby-Teglund A, Stevens DL. Novel therapies in streptococcal toxic shock syndrome: attenuation of virulence factor expression and modulation of the host response. Curr Opin Infect Dis. 1998. 11:285–291.